WPG Advisers’s Travere Therapeutics TVTX Stock Holding History

WPG Advisers’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-42	Closed	-$753	–	1498
2025 Q1	$753	Buy	42 +2	+5%	+$41	﹤0.01%	1304
2024 Q4	$697	Buy	+40	New	+$707	﹤0.01%	1280

Other funds holding TVTX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

WPG Advisers's TVTX Position: Q2 2025 in Review

WPG Advisers sold out of Travere Therapeutics (TVTX) in Q2 2025, closing a stake of 42 shares — an estimated $753 sold.

WPG Advisers first reported a position in TVTX in Q4 2024 and held it in 2 quarters. The position peaked at $753 in Q1 2025. 211 funds tracked by Wall St. Rank hold TVTX as of Q2 2025.

WPG Advisers reported no remaining Travere Therapeutics position as of Q2 2025 after selling out during the quarter.
WPG Advisers sold 42 Travere Therapeutics shares in Q2 2025, an estimated $753.
WPG Advisers first reported a position in Travere Therapeutics in Q4 2024 and held it in 2 quarters.
WPG Advisers's Travere Therapeutics position peaked at $753 in Q1 2025.
211 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2025.

Based on WPG Advisers's 13F filing for Q2 2025, filed 11 Aug 2025.